FUJIFILM Holdings Website. ET by Tomi Kilgore Xerox's stock sinks after dropping Fujifilm merger prompts analyst downgrade The massive jump in an otherwise bearish market came as China suggested that an influenza medicine developed by subsidiary FUJIFILM Toyama Chemical Co. Ltd. is … Avigan undergoes an intracellular phosphoribosylation to become an active form and then inhibits RNA polymerase activity.As the catalytic domain of RdRp is conserved among various types of RNA viruses, that mechanism of action supports a wide spectrum of potential activity. The medicine has a stockpile sufficient for 2 million patients, and the company will make a decision about additional production after monitoring the situation.Avigan functions as an antiviral drug against RNA viruses.
The share price ended the day at ¥5,567, for a gain of 2.83%.
14, 2018 at 9:45 a.m. The French Institute of Health and Medical Research then carried out a clinical trial on Avigan’s efficacy as a treatment for EVD at four medical institutes in Guinea from December 2014 to May 2015. The website of FUJIFILM Toyama Chemical Co., Ltd.. Avigan works against a broad range of influenza virus types as well as West Nile virus, yellow fever, foot-and-mouth disease, and other flaviviruses, arenaviruses, bunyaviruses and alphaviruses, he noted.In October 2014, a French nurse with Ebola virus who was treated with a combination of Avigan and other drugs recovered. The drug has not been approved by the Korean government at this point.The medication attracted market attention when Minister of Health, Labor and Welfare Katsunobu Kato said on Feb. 22 that the country is planning to test Avigan against COVID-19. FUJIFILM Toyama Chemical was formed through the merger of TOYAMA CHEMICAL CO., LTD. Company profile page for FUJIFILM Toyama Chemical Co Ltd including stock price, company news, press releases, executives, board members, and contact information The drug was approved for use in Japan in 2014.But a Fujifilm spokesman said the company expects no direct earnings impact from potential sales growth of Favipiravir in China, at least for now, as its license for the key ingredient in the country already expired last year. The introduction about corporate profile, our R&D efforts, and news. Kato said the ministry would test how effective flu medicines are at treating the disease and allow many medical institutions in Japan to use them for patients if needed.As of Feb. 25, more than 850 cases have been confirmed in Japan.As of Feb. 25 in Korea, the number of COVID-19 cases has rapidly soared to more than 1,000, of which most cases are from a church community.